Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
- Oppenheimer analyst Suraj Kalia initiated coverage on Abbott Laboratories (NYSE:ABT) with an Outperform rating and announced a price target of $130. Abbott shares gained 0.6% to close at $113.36 on Monday. See how other analysts view this stock.
- Wells Fargo analyst Eva Fortea Verdejo initiated coverage on Arcus Biosciences, Inc. (NYSE:RCUS) with an Overweight rating and announced a price target of $29. Arcus Biosciences shares gained 3.9% to close at $17.30 on Monday. See how other analysts view this stock.
- Susquehanna analyst Charles Minervino initiated coverage on Howmet Aerospace Inc. (NYSE:HWM) with a Positive rating and announced a price target of $120. Howmet Aerospace shares gained 0.8% to close at $102.83 on Monday. See how other analysts view this stock.
- Morgan Stanley analyst Judah Frommer initiated coverage on Bicara Therapeutics Inc. (NASDAQ:BCAX) with an Overweight rating and announced a price target of $35. Bicara Therapeutics shares fell 2.8% to close at $24.45 on Monday. See how other analysts view this stock.
- Hovde Group initiated coverage on First National Corporation (NASDAQ:FXNC) with an Outperform rating and announced a price target of $22. First National shares gained 0.9% to close at $18.37 on Monday. See how other analysts view this stock.
Considering buying ABT stock? Here's what analysts think:
Read More:
- Dow Dips Around 400 Points As Treasury Yields Top 4%: Investor Optimism Declines, But Fear Index Remains In 'Greed' Zone
